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Propositions 
 
belonging to the thesis 
Cisp la t in  res i s tance  in  urothe l ia l  carc inoma 
Un de r s t a n d ing  an d  t a r g e t i n g  i nhe r en t  and  a cqu i r e d  me ch an i s ms  
 
 
1. CD90+/CK14+ do not specifically mark cancer stem cells in urothelial carcinoma 
cell lines and do not correlate under various conditions (this dissertation). 
 
2. Long-term cisplatin treated urothelial carcinoma cell lines (LTTs) evade cisplatin 
induced cell death through phenotypic plasticity towards an EMT-like phenotype 
(this dissertation).  
 
3. Each LTT contains an individual assortment of resistance mechanisms at 
multiple levels (this dissertation). 
 
4. Approaches targeting individual resistance mechanisms are only partly efficacious 
(this dissertation). 
 
5. The chicken chorioallantoic membrane (CAM) assay is an attractive 3D model to 
study urothelial carcinoma and can be used as an alternative approach to murine 
in vivo studies; however, the short timing can be a limiting factor (this dissertation). 
 
6. It is an old saying, abundantly justified, that where sciences meet there growth 
occurs. - Sir Frederick Gowland Hopkins 
 
7. Success in research needs persistence and consequence. 
 
8. I have not failed. I’ve just found 10,000 ways that won’t work. - Thomas Edison 
 
9. The conviction that the right approach to solve the task is to do it rationally does 
not prevent a scientist from hoping for unexpected lucky coincidence, 
serendipity. 
 
10. A scientist in his laboratory is not a mere technician; he is also a child 
confronting natural phenomena that impress him as though they were fairy tales. 
- Maria Skłodowska-Curie 
 
11. What people call serendipity sometimes is just having your eyes open. - Jose 
Manuel Barroso 
 
Margaretha A. Skowron 
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